NCT00730145View on ClinicalTrials.gov

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Renal DialysisPharmacokinetics
Interventions
DRUG

PD-0332334

A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject

Trial Locations (1)

32809

Pfizer Investigational Site, Orlando

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY